Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
Journal
American Journal of Nephrology
ISSN
0250-8095
1421-9670
Publisher
Karger Publishers
Date Issued
2023
Author(s)
Macdougall, Iain C.
Meadowcroft, Amy M.
Blackorby, Allison
Cizman, Borut
Cobitz, Alexander R.
Godoy, Sergio
Jha, Vivekanand
Johansen, Kirsten L.
McMahon, Gearoid
Wong, Muh Geot
Singh, Ajay K.
Type
Resource Types::text::journal::journal article
Abstract
Introduction: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) affects 10-15% of the chronic dialysis population. We explored baseline characteristics and predictors of ESA hyporesponsiveness in a global randomized cardiovascular outcomes study comparing an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), daprodustat, with conventional ESA treatment. Methods: ASCEND-D (NCT02879305) recruited 2,964 chronic dialysis patients receiving ESA treatment (standardized to weekly intravenous [IV] epoetin) who were iron replete at baseline. The primary ESA hyporesponsiveness definition was an ESA Resistance Index (ERI, ESA units/kg/week/hemoglobin g/L) ≥2 or IV standardized ESA dose ≥450 units/kg/week. Predictors of ESA hyporesponsiveness were determined using a multivariable regression model. Alternative hyporesponder definitions were explored. The Author(s). Published by S. Karger AG, Basel.
How to cite
Macdougall, I. C., Meadowcroft, A. M., Blackorby, A., Cizman, B., Cobitz, A. R., Godoy, S., Jha, V., Johansen, K. L., McMahon, G., Obrador, G. T., Wong, M. G., & Singh, A. K. (2023). Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). In American Journal of Nephrology (Vol. 54, Issues 1–2, pp. 1–13). S. Karger AG. https://doi.org/10.1159/000528696